These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 12036002)

  • 1. Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI.
    French MT; Salomé HJ; Sindelar JL; McLellan AT
    Health Serv Res; 2002 Apr; 37(2):433-55. PubMed ID: 12036002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington.
    French MT; Salomé HJ; Carney M
    Soc Sci Med; 2002 Dec; 55(12):2267-82. PubMed ID: 12409139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the economic cost of substance abuse treatment.
    French MT; McGeary KA
    Health Econ; 1997; 6(5):539-44. PubMed ID: 9353658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the client costs of addiction treatment: first findings from the client drug abuse treatment cost analysis program (Client DATCAP).
    Salomé HJ; French MT; Miller M; McLellan AT
    Drug Alcohol Depend; 2003 Aug; 71(2):195-206. PubMed ID: 12927658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A structured instrument for estimating the economic cost of drug abuse treatment. The Drug Abuse Treatment Cost Analysis Program (DATCAP).
    French MT; Dunlap LJ; Zarkin GA; McGeary KA; McLellan AT
    J Subst Abuse Treat; 1997; 14(5):445-55. PubMed ID: 9437614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost estimation when time and resources are limited: the Brief DATCAP.
    French MT; Roebuck MC; McLellan AT
    J Subst Abuse Treat; 2004 Oct; 27(3):187-93. PubMed ID: 15501371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes.
    Sindelar JL; Jofre-Bonet M; French MT; McLellan AT
    Drug Alcohol Depend; 2004 Jan; 73(1):41-50. PubMed ID: 14687958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit-cost analysis of residential and outpatient addiction treatment in the State of Washington.
    French MT; Salomé HJ; Krupski A; McKay JR; Donovan DM; McLellan AT; Durell J
    Eval Rev; 2000 Dec; 24(6):609-34. PubMed ID: 11151519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines and challenges for estimating the economic costs and benefits of adolescent substance abuse treatments.
    Zavala SK; French MT; Henderson CE; Alberga L; Rowe C; Liddle HA
    J Subst Abuse Treat; 2005 Oct; 29(3):191-205. PubMed ID: 16183468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and cost-effectiveness of four treatment modalities for substance disorders: a propensity score analysis.
    Mojtabai R; Zivin JG
    Health Serv Res; 2003 Feb; 38(1 Pt 1):233-59. PubMed ID: 12650390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"?
    Ettner SL; Huang D; Evans E; Ash DR; Hardy M; Jourabchi M; Hser YI
    Health Serv Res; 2006 Feb; 41(1):192-213. PubMed ID: 16430607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presentation and validation of the Abbreviated Self Completion Teen-Addiction Severity Index (ASC T-ASI): A preference-based measure for use in health-economic evaluations.
    Reckers-Droog V; Goorden M; Kaminer Y; van Domburgh L; Brouwer W; Hakkaart-van Roijen L
    PLoS One; 2020; 15(9):e0238858. PubMed ID: 32915870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Service-level costing of drug abuse treatment.
    Anderson DW; Bowland BJ; Cartwright WS; Bassin G
    J Subst Abuse Treat; 1998; 15(3):201-11. PubMed ID: 9633032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using cost and financing instruments for economic evaluation of substance abuse treatment services.
    Salomé HJ; French MT
    Recent Dev Alcohol; 2001; 15():253-69. PubMed ID: 11449745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A profile of the substance abuse treatment industry: organization, costs, and treatment completion.
    Woodward AM; Raskin IE; Blacklow B
    Subst Use Misuse; 2008; 43(5):647-79. PubMed ID: 18393082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DATStats: results from 85 studies using the Drug Abuse Treatment Cost Analysis Program.
    Roebuck MC; French MT; McLellan AT
    J Subst Abuse Treat; 2003 Jul; 25(1):51-7. PubMed ID: 14512108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economic cost of outpatient marijuana treatment for adolescents: findings from a multi-site field experiment.
    French MT; Roebuck MC; Dennis ML; Diamond G; Godley SH; Tims F; Webb C; Herrell JM
    Addiction; 2002 Dec; 97 Suppl 1():84-97. PubMed ID: 12460131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit-cost analysis of addiction treatment in Arkansas: specialty and standard residential programs for pregnant and parenting women.
    French MT; McCollister KE; Cacciola J; Durell J; Stephens RL
    Subst Abus; 2002 Mar; 23(1):31-51. PubMed ID: 12444359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating primary medical care with addiction treatment: a randomized controlled trial.
    Weisner C; Mertens J; Parthasarathy S; Moore C; Lu Y
    JAMA; 2001 Oct; 286(14):1715-23. PubMed ID: 11594896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.